Skip to main content
. 2017 May;5(5):E324–E330. doi: 10.1055/s-0043-104860

Table 1. Patients characteristics of the total study group (n = 75).

Characteristic n %
Men/women 55/20 73.3/26.7
Mean age (years) 71.7 (range 45 – 92)
Active bleeding source

  • Upper GI tract

 68/75 90.7
– Esophagus  3/75  4.0
– Stomach 22/75 29.3
– Duodenum 43/75 57.3

  • Lower GI tract

  7/75  9.3
– Colon  4/75  5.3
– Rectum  3/75  4.0
Type of lesion

  • Ulcer

 62/75 82.7

  • Postinterventional1

10/75 13.3

  • Varia2

 3/75  4.0
Bleeding source in upper GI tract

  • Duodenal ulcer

 41/62 66.1

  • Gastric ulcer

 18/62 29.0
Forrest classification

  • Ia

 18/75 24.0

  • Ib

 33/75 44.0

  • IIa

 22/75 29.3

  • IIb

  2/75  2.7
Antithrombotic therapy
No therapy 18/75 24.0
Antiplatelet therapy 44/75
 58.7

  • Antiplatelet monotherapy

 34/75 45.8
– Aspirin 26/75 34.7
– Clopidogrel  8/75 10.7

  • Dual antiplatelet therapy (DAPT)

 10/75 13.3
Inhibitors of plasmatic coagulation 13/75 17.3
Combination therapy3 12/75 16.0

GI, gastrointestinal; EMR, endoscopic mucosal resection

1

surgery, polypectomy, PEG-removal, EMR;

2

Mallory Weiss lesion, diverticular bleeding;

3

patients with combination therapy are also included in the “antiplatelet therapy” and “inhibitors of plasmatic coagulation” group